Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
6.88
-0.20 (-2.82%)
Oct 30, 2025, 12:52 PM EDT - Market open
Evolent Health Revenue
Evolent Health had revenue of $444.33M in the quarter ending June 30, 2025, a decrease of -31.34%. This brings the company's revenue in the last twelve months to $2.20B, down -6.71% year-over-year. In the year 2024, Evolent Health had annual revenue of $2.55B with 30.09% growth.
Revenue (ttm)
$2.20B
Revenue Growth
-6.71%
P/S Ratio
0.37
Revenue / Employee
$487,982
Employees
4,500
Market Cap
797.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.55B | 590.85M | 30.09% |
| Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
| Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
| Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
| Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EVH News
- 21 days ago - Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - PRNewsWire
- 5 weeks ago - Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners - PRNewsWire
- 2 months ago - Evolent's Soft Q2 Results: Why I'm Holding Anyway - Seeking Alpha
- 2 months ago - Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 2 months ago - Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 2 months ago - Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evolent Announces Second Quarter 2025 Results - PRNewsWire
- 3 months ago - Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - PRNewsWire